Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

Published

News published by Avalyn Pharma concerning AP01 (inhaled pirfenidone), administered via an optimized eFlow® Technology nebulizer.

 

Read the press release

Back to overview